SCHEMBL13638310

SCHEMBL13638310

C=C1CC(Nc2nccc(-c3ccc4sccc4c3)n2)CC(C)(C)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.37
IKBKB O14920 6/20 0.36
AURKA O14965 1/20 0.36
TTK P33981 1/20 0.36
AURKB Q96GD4 1/20 0.36
INCENP Q9NQS7 1/20 0.36
CHRNA7 P36544 3/20 0.36
KCNH2 Q12809 3/20 0.36
DYRK2 Q92630 2/20 0.34
MAPK8 P45983 2/20 0.34
HDAC8 Q9BY41 2/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA2 P20248 1/20 0.33
CCND1 P24385 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472008 0.86 KCNH2 (0.43) KDM1AIKBKBAURKATTKAURKB
SCHEMBL13638584 0.84 KCNH2 (0.47) IKBKBAURKATTKAURKBINCENP
SCHEMBL14612807 0.82 IKBKB (0.44) IKBKBAURKATTKAURKBINCENP
SCHEMBL13638533 0.81 IKBKB (0.43) IKBKBMAPK8HDAC8MAPK9MAPK10
SCHEMBL13638440 0.81 IKBKB (0.43) IKBKBAURKATTKAURKBINCENP
SCHEMBL13638678 0.81 IKBKB (0.42) IKBKBAURKATTKAURKBINCENP
SCHEMBL14612854 0.79 IKBKB (0.42) IKBKBAURKATTKAURKBINCENP
SCHEMBL13638436 0.79 IKBKB (0.42) IKBKBAURKATTKAURKBINCENP
SCHEMBL14612808 0.79 HDAC8 (0.44) IKBKBMAPK8HDAC8
SCHEMBL14612864 0.77 IKBKB (0.48) IKBKBKCNH2MAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK KDM1A 1291/4885IKBKB 2/4885AURKA 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.